For research use only. Not for therapeutic Use.
Troglitazone（Cat No.:I005713）is a thiazolidinedione class drug primarily used for the management of type 2 diabetes. It acts as a selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ), promoting insulin sensitivity and enhancing glucose uptake in adipose tissue, muscle, and liver. Troglitazone not only improves glycemic control but also has beneficial effects on lipid profiles. However, its clinical use was limited due to reports of severe liver toxicity, leading to its withdrawal from the market. Despite this, troglitazone’s mechanism of action has provided insights into the development of safer PPARγ agonists for diabetes treatment.
| Catalog Number | I005713 |
| CAS Number | 97322-87-7 |
| Synonyms | CS-045 |
| Molecular Formula | C24H27NO5S |
| Purity | ≥95% |
| Target | Vitamin D Related/Nuclear Receptor |
| Solubility | DMSO:>25 mg/ml; DMF：30 mg/ml; |
| Storage | Store at -20°C |
| IC50 | 5.71 uM and 8.38 uM (in 786-O and A498 cells) |
| IUPAC Name | 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| InChI | InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28) |
| InChIKey | GXPHKUHSUJUWKP-UHFFFAOYSA-N |
| SMILES | CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C |
| Reference | </br>1:Troglitazone inhibits bile acid amidation: a possible risk factor for liver injury. Ogimura E, Nakagawa T, Deguchi J, Sekine S, Ito K, Bando K.Toxicol Sci. 2017 May 9. doi: 10.1093/toxsci/kfx091. [Epub ahead of print] PMID: 28486596 </br>2:Correction: Combined Treatment with Troglitazone and Lovastatin Inhibited Epidermal Growth Factor-Induced Migration through the Downregulation of Cysteine-Rich Protein 61 in Human Anaplastic Thyroid Cancer Cells. Chin LH, Hsu SP, Zhong WB, Liang YC.PLoS One. 2017 May 8;12(5):e0177545. doi: 10.1371/journal.pone.0177545. eCollection 2017. PMID: 28481927 Free PMC Article</br>3:PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Nazim UM, Moon JH, Lee YJ, Seol JW, Park SY.Oncotarget. 2017 Apr 18;8(16):26819-26831. doi: 10.18632/oncotarget.15819. PMID: 28460464 Free PMC Article</br>4:Arsenic, Cadmium, and Lead Like Troglitazone Trigger PPARγ-Dependent Poly (ADP-Ribose) Polymerase Expression and Subsequent Apoptosis in Rat Brain Astrocytes. Kushwaha R, Mishra J, Tripathi S, Khare P, Bandyopadhyay S.Mol Neurobiol. 2017 Mar 10. doi: 10.1007/s12035-017-0469-7. [Epub ahead of print] PMID: 28283887 </br>5:Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions. Berthe A, Flament S, Grandemange S, Zaffino M, Boisbrun M, Mazerbourg S.Cell Cycle. 2016 Dec 16;15(24):3402-3412. doi: 10.1080/15384101.2016.1245248. Epub 2016 Oct 18. PMID: 27753533 </br>6:Differential secretion of adipokines from subcutaneous and visceral adipose tissue in healthy dogs: Association with body condition and response to troglitazone. Mazaki-Tovi M, Bolin SR, Schenck PA.Vet J. 2016 Oct;216:136-41. doi: 10.1016/j.tvjl.2016.08.002. Epub 2016 Aug 10. PMID: 27687941 </br>7:Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro. Zhu HY, Bai WD, Li J, Tao K, Wang HT, Yang XK, Liu JQ, Wang YC, He T, Xie ST, Hu DH.Am J Transl Res. 2016 Aug 15;8(8):3460-70. eCollection 2016. PMID: 27648136 Free PMC Article</br>8:Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy. Park H, Ko SH, Lee JM, Park JH, Choi YH.Yonsei Med J. 2016 Nov;57(6):1494-9. doi: 10.3349/ymj.2016.57.6.1494. PMID: 27593880 Free PMC Article</br>9:Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment? Mazerbourg S, Kuntz S, Grillier-Vuissoz I, Berthe A, Geoffroy M, Flament S, Bordessa A, Boisbrun M.Curr Top Med Chem. 2016;16(19):2115-24. Review. PMID: 26881718 </br>10:Cancer drug troglitazone stimulates the growth and response of renal cells to hypoxia inducible factors. Taub M.Biochem Biophys Res Commun. 2016 Mar 11;471(3):342-7. doi: 10.1016/j.bbrc.2016.02.018. Epub 2016 Feb 8. PMID: 26869517 |
